Clinical Trials on Adult Lymphocyte Predominant Hodgkin Lymphoma

Total 6584 results

National Cancer Institute (NCI)

Completed

Bortezomib, Ifosfamide, and Vinorelbine Tartrate in Treating Young Patients With Hodgkin's Lymphoma That is Recurrent or Did Not Respond to Previous Therapy

Recurrent Adult Hodgkin Lymphoma | Stage III Adult Hodgkin Lymphoma | Stage IV Adult Hodgkin Lymphoma | Recurrent/Refractory Childhood Hodgkin Lymphoma | Stage III Childhood Hodgkin Lymphoma | Stage IV Childhood Hodgkin Lymphoma | Stage I Adult Hodgkin Lymphoma | Stage I Childhood Hodgkin Lymphoma | Stage II Adult Hodgkin Lymphoma and other conditions

United States
Ohio State University Comprehensive Cancer Center
Novartis; Celgene

Completed

A Phase II Trial of Panobinostat and Lenalidomide in Patients With Relapsed or Refractory Hodgkin's Lymphoma

Recurrent Adult Hodgkin Lymphoma | Adult Lymphocyte Depletion Hodgkin Lymphoma | Adult Lymphocyte Predominant Hodgkin Lymphoma | Adult Mixed Cellularity Hodgkin Lymphoma | Adult Nodular Sclerosis Hodgkin Lymphoma | Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma

United States
Beth Christian

Completed

Gemcitabine and Bendamustine in Patients With Relapsed or Refractory Hodgkin's Lymphoma

Recurrent Adult Hodgkin Lymphoma | Adult Lymphocyte Depletion Hodgkin Lymphoma | Adult Lymphocyte Predominant Hodgkin Lymphoma | Adult Mixed Cellularity Hodgkin Lymphoma | Adult Nodular Sclerosis Hodgkin Lymphoma | Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma

United States
National Cancer Institute (NCI)

Completed

Vorinostat in Treating Patients With Relapsed or Refractory Advanced Hodgkin's Lymphoma

Recurrent Adult Hodgkin Lymphoma | Adult Lymphocyte Depletion Hodgkin Lymphoma | Adult Lymphocyte Predominant Hodgkin Lymphoma | Adult Mixed Cellularity Hodgkin Lymphoma | Adult Nodular Sclerosis Hodgkin Lymphoma | Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma | Adult Favorable Prognosis... and other conditions

United States
National Cancer Institute (NCI)

Completed

SGN-30 and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

Recurrent Adult Hodgkin Lymphoma | Adult Lymphocyte Depletion Hodgkin Lymphoma | Adult Lymphocyte Predominant Hodgkin Lymphoma | Adult Mixed Cellularity Hodgkin Lymphoma | Adult Nodular Sclerosis Hodgkin Lymphoma

United States
Northwestern University
Seagen Inc.; Robert H. Lurie Cancer Center

Unknown

Brentuximab Vedotin and Combination Chemotherapy in Treating Older Patients With Previously Untreated Stage II-IV Hodgkin Lymphoma

Stage III Adult Hodgkin Lymphoma | Stage IV Adult Hodgkin Lymphoma | Stage II Adult Hodgkin Lymphoma | Adult Lymphocyte Depletion Hodgkin Lymphoma | Adult Lymphocyte Predominant Hodgkin Lymphoma | Adult Mixed Cellularity Hodgkin Lymphoma | Adult Nodular Sclerosis Hodgkin Lymphoma

United States
University of Cologne

Completed

Ibrutinib in Relapsed Nodular Lymphocyte-predominant Hodgkin Lymphoma (NLPHL) (IRENO)

Nodular Lymphocyte-Predominant Hodgkin's Lymphoma

Germany
National Cancer Institute (NCI)

Recruiting

Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma

Nodular Lymphocyte Predominant B-Cell Lymphoma | Recurrent Nodular Lymphocyte Predominant B-Cell Lymphoma | Refractory Nodular Lymphocyte Predominant B-Cell Lymphoma

United States
St. Jude Children's Research Hospital

Recruiting

Patient-Reported Outcomes and Quality of Life in Adult and Pediatric Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL)

Nodular Lymphocyte-Predominant Hodgkin Lymphoma

United States
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Completed

CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma

Peripheral T-cell Lymphoma | Anaplastic Large Cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Adult Nasal Type Extranodal NK/T-cell Lymphoma | Hepatosplenic T-cell Lymphoma | Recurrent Adult Acute Lymphoblastic Leukemia | Recurrent Adult Hodgkin Lymphoma | Recurrent Adult T-cell Leukemia/Lymphoma and other conditions

United States
University of Cologne

Completed

Rituximab in Primary Lymphocyte Predominant Hodgkin´s Disease(RIPL)

Lymphocyte Predominant Hodgkin´s Lymphoma (LPHD)

Germany
Ranjana Advani
Genentech, Inc.

Completed

Rituximab in Treating Patients With Hodgkin's Lymphoma

Lymphoma | Hodgkin Lymphoma (Category) | Nodular Lymphocyte Predominant Hodgkin Lymphoma

United States
Christine Mauz-Körholz
Deutsche Krebshilfe e.V., Bonn (Germany); Euronet Worldwide

Completed

Surgery Alone or With CYC VBL and PRED or CVP Alone in Stage IA or IIA Nodular Lymphocyte-Predominant Hodgkin Lymphoma (EuroNetLP1)

Lymphoma

Germany
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Combination Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin Lymphoma

Stage III Childhood Hodgkin Lymphoma | Stage IV Childhood Hodgkin Lymphoma | Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma

United States, Canada, Israel, Australia, Puerto Rico
National Cancer Institute (NCI)

Completed

Bortezomib in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma

Recurrent Adult Hodgkin Lymphoma | Adult Lymphocyte Depletion Hodgkin Lymphoma | Adult Mixed Cellularity Hodgkin Lymphoma | Adult Nodular Sclerosis Hodgkin Lymphoma

United States
University of Cologne

Completed

Ofatumumab in Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL)

Relapsed NLPHL

Germany
National Cancer Institute (NCI)

Terminated

CCI-779 in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Hodgkin Lymphoma | Refractory Chronic Lymphocytic Leukemia

United States
University of Giessen

Completed

Bendamustine Plus Rituximab Versus CHOP Plus Rituximab

Marginal Zone Lymphomas | Non-Hodgkin Lymphomas | Follicular Lymphomas | Immunocytomas | Lymphocytic Lymphomas

Germany
Jonsson Comprehensive Cancer Center
Gilead Sciences

Terminated

Mechanisms of Idelalisib-Associated Diarrhea in Patients With Relapsed Chronic Lymphocytic Leukemia, Indolent Non-hodgkin Lymphoma, or Small Lymphocytic Lymphoma

B-Cell Non-Hodgkin Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Chronic Lymphocytic Leukemia | Recurrent Indolent Adult Non-Hodgkin Lymphoma | Absence of Signs or Symptoms | Digestive System Signs and Symptoms | Indolent Adult Non-Hodgkin Lymphoma

United States
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Chemotherapy With or Without Additional Chemotherapy and/or Radiation Therapy in Treating Children With Newly Diagnosed Hodgkin's Disease

Stage III Childhood Hodgkin Lymphoma | Stage IV Childhood Hodgkin Lymphoma | Stage I Childhood Hodgkin Lymphoma | Stage II Childhood Hodgkin Lymphoma | Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma | Childhood Lymphocyte-Depleted Classical Hodgkin Lymphoma | Childhood Mixed Cellularity... and other conditions

United States, Canada, Australia, New Zealand, Puerto Rico, Switzerland, Israel
National Cancer Institute (NCI)

Terminated

Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent... and other conditions

United States
National Cancer Institute (NCI)

Terminated

Fenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma

Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Lymphoblastic Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone... and other conditions

United States
Baylor College of Medicine
The Methodist Hospital Research Institute; Center for Cell and Gene Therapy...

Recruiting

CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies (ANCHOR)

Refractory B-Cell Non-Hodgkin Lymphoma | Relapsed Non Hodgkin Lymphoma | Relapsed Adult ALL | Relapsed CLL | Refractory B-Cell Small Lymphocytic Lymphoma

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma

Refractory Hodgkin Lymphoma | Recurrent Adult Hodgkin Lymphoma | Recurrent Small Lymphocytic Lymphoma | Prolymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | T-Cell Chronic Lymphocytic Leukemia | Recurrent Childhood Non-Hodgkin... and other conditions

United States, Germany
Precision BioSciences, Inc.

Completed

Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLL

Lymphoma, Non-Hodgkin | Chronic Lymphocytic Leukemia | B-cell Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma | B-cell Non Hodgkin Lymphoma | Leukemia, Lymphocytic, Chronic | Non-Hodgkin's Lymphoma, Relapsed | Non-Hodgkin's Lymphoma Refractory | Chronic Lymphoid Leukemia in Relapse

United States
National Cancer Institute (NCI)

Completed

Tipifarnib in Treating Patients With Relapsed or Refractory Lymphoma

Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Splenic Marginal Zone Lymphoma | Anaplastic Large Cell Lymphoma | Recurrent Adult Hodgkin Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent... and other conditions

United States
OHSU Knight Cancer Institute
National Cancer Institute (NCI)

Completed

Vorinostat, Cladribine, and Rituximab in Treating Patients With Mantle Cell Lymphoma, Relapsed Chronic Lymphocytic Leukemia, or Relapsed B Cell Non-Hodgkin's Lymphoma

Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Chronic Lymphocytic Leukemia | Recurrent Indolent Adult Non-Hodgkin Lymphoma

United States
Genentech, Inc.

Completed

A Study of Escalating Doses of Polatuzumab Vedotin in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma and Chronic Lymphocytic Leukemia and Polatuzumab Vedotin in Combination With Rituximab in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma

Chronic Lymphocytic Leukemia | Non-Hodgkins Lymphoma

United States, France, Canada, Netherlands
A.O. Ospedale Papa Giovanni XXIII

Active, not recruiting

Blinatumomab Expanded T-cells (BET) in Indolent Non-Hodgkin Lymphomas/Chronic Lymphocytic Leukemia (BET2017)

Indolent Non-Hodgkin Lymphomas/Chronic Lymphocytic Leukemia

Italy
Children's Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

Treating Young Patients With Newly Diagnosed, Low Stage, Lymphocyte Predominant Hodgkin Disease

Ann Arbor Stage I Childhood Hodgkin Lymphoma | Ann Arbor Stage II Childhood Hodgkin Lymphoma | Childhood Nodular Lymphocyte Predominant B-Cell Lymphoma

United States, Canada, Australia, New Zealand, Puerto Rico, Israel
Estrella Biopharma, Inc.
Eureka Therapeutics Inc.

Not yet recruiting

T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) (Starlight-1)

Lymphoma | Lymphoma, Non-Hodgkin | Non-Hodgkin's Lymphoma | Non-Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | High-grade B-cell Lymphoma | CNS Lymphoma | Lymphomas Non-Hodgkin's B-Cell | Relapsed Non-Hodgkin Lymphoma | Lymphoma, Non-Hodgkins | Large B-Cell Lymphoma and other conditions
Gilead Sciences
Ono Pharmaceutical Co. Ltd

Completed

Study to Evaluate the Safety and Tolerability of Tirabrutinib (ONO/GS-4059) Given as Monotherapy in Participants With Relapsed/Refractory NHL and CLL

Chronic Lymphocytic Leukaemia | Non Hodgkins Lymphoma

United Kingdom, France
National Cancer Institute (NCI)

Terminated

T Cells Expressing Fully-human Anti-CD19 and Anti-CD20 Chimeric Antigen Receptors for Treating B-cell Malignancies and Hodgkin Lymphoma

Lymphoma, B-Cell | Chronic Lymphocytic Leukemia | Lymphoma, Non-hodgkins | B-Cell Chronic Lymphocytic Leukemia

United States
National Cancer Institute (NCI)

Completed

Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma | Recurrent Adult Immunoblastic... and other conditions

United States
Nanjing Sanhome Pharmaceutical, Co., Ltd.

Unknown

Safety, Tolerability, and Pharmacokinetics of SHC014748M in Patients With Indolent B-Cell Hematologic Malignancies

Chronic Lymphocytic Leukemia (CLL) | Small Lymphocytic Lymphoma (SLL) | B-Cell Non-Hodgkin Lymphomas(NHL)

China
Genentech, Inc.

Completed

A Study of the Safety and Pharmacokinetics of Escalating Doses of DCDT2980S in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia And DCDT2980S in Combination With Rituximab in Patients With Relapsed or Refractory B-Cell Non Hodgkin's Lymphoma

Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia

United States
Tomsk National Research Medical Center of the Russian...
Uppsala University

Completed

Molecular Imaging of Lymphoma Using Labeled Technetium-99m 1-Thio-D-Glucose

Hodgkin Lymphoma, Adult | Non-Hodgkin Lymphoma, Adult

Russian Federation
National Cancer Institute (NCI)

Completed

Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery

Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma | Recurrent Adult Lymphoblastic Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma and other conditions

United States
National Cancer Institute (NCI)

Completed

Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma

Recurrent Adult Burkitt Lymphoma | Recurrent Adult Lymphoblastic Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Splenic Marginal Zone Lymphoma | Waldenstrom... and other conditions

United States
Grupo Argentino de Tratamiento de la Leucemia Aguda
Takeda

Recruiting

RWE of Brentuximab Vedotin Consolidation in Patients With RR HL Who Receive Salvage Chemotherapy and ASCT

Refractory Hodgkin Lymphoma | Hodgkin Lymphoma, Adult | Relapsed Hodgkin's Disease, Adult

Argentina
Sidney Kimmel Cancer Center at Thomas Jefferson...
GlaxoSmithKline; Novartis

Terminated

Combination of Pentostatin, Bendamustine and Ofatumumab for Treatment of Chronic Lymphocytic Leukemia and Lymphoma

Chronic Lymphocytic Leukemia | B-Cell Non-Hodgkin's Lymphoma

United States
Gilead Sciences

Completed

Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia

Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Indolent Non-Hodgkin's Lymphoma

United States
National Cancer Institute (NCI)

Terminated

Oblimersen and Gemcitabine in Treating Patients With Advanced Solid Tumor or Lymphoma

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma and other conditions

United States
AbbVie
Infinity Pharmaceuticals, Inc.

Withdrawn

A Study of Duvelisib and Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Indolent or Aggressive Non-Hodgkin Lymphoma, Who Have Not Previously Received a Bcl-2 or PI3K Inhibitor

Chronic Lymphocytic Leukemia | Non-Hodgkin Lymphoma | Small Lymphocytic Lymphoma

United States
MedImmune LLC

Completed

Safety Study of CAT-8015 to Treat Advanced B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia (NHL or CLL)

Chronic Lymphocytic Leukemia | Non-Hodgkin Lymphoma

United States, Poland
University of Chicago
National Cancer Institute (NCI)

Active, not recruiting

Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Splenic Marginal Zone Lymphoma | Waldenström Macroglobulinemia | Cutaneous B-cell Non-Hodgkin Lymphoma | Intraocular Lymphoma | Small Intestine Lymphoma | Testicular Lymphoma | B-cell... and other conditions

United States
GlyPharma Therapeutics
VectivBio AG

Withdrawn

Safety, Tolerability, PK/PD of FE 203799 in Adults With Lymphomas

Lymphoma, Non-Hodgkin's, Adult | Lymphoma, Hodgkin's, Adult
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); National Heart, Lung, and Blood Institute...

Withdrawn

HIV-Resistant Gene Modified Stem Cells and Chemotherapy in Treating Patients With Lymphoma With HIV Infection

Stage III Adult Hodgkin Lymphoma | Stage IV Adult Hodgkin Lymphoma | Human Immunodeficiency Virus 1 Positive | Stage I Adult Hodgkin Lymphoma | Stage II Adult Hodgkin Lymphoma | Stage I Adult Non-Hodgkin Lymphoma | Stage II Adult Non-Hodgkin Lymphoma | Stage III Adult Non-Hodgkin Lymphoma | Stage IV...

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia

Waldenstrom Macroglobulinemia | Refractory Plasma Cell Myeloma | Recurrent Adult Hodgkin Lymphoma | Recurrent Adult Non-Hodgkin Lymphoma | Recurrent Small Lymphocytic Lymphoma | Refractory Chronic Lymphocytic Leukemia | Refractory Non-Hodgkin Lymphoma | Recurrent Plasma Cell Myeloma | Plasma Cell Leukemia and other conditions

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Terminated

Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma and other conditions

United States

Clinical Trials on Adult Lymphocyte Predominant Hodgkin Lymphoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Saudi Arabia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations